Inviragen forms dengue partnership with IVI

Vaccine maker Inviragen has signed a memorandum of understanding with the nonprofit International Vaccine Institute (IVI) for further development of dengue vaccines. Currently, Inviragen has a tetravalent dengue vaccine, DENvax, in two Phase I clinical trials.

Rather than simply focusing on the vaccine itself, this partnership will look to make policy and regulatory changes to assist dengue vaccine adoption in low- and middle-income countries where the disease is prevalent. Dengue has already affected 120 countries, and 2.5 billion people are at risk of developing the disease.

"The [IVI], in collaboration with Inviragen, a company that has shown a commitment to developing a vaccine for dengue, plans to expedite the collective goal of developing and introducing a safe, effective and affordable dengue vaccine in the near future," said Dr. Luiz da Silva, director of the Dengue Vaccine Initiative, of which IVI is a part, in a release. "Dengue is not simply a public health threat but can have a catastrophic effect on the economic status of those living in poverty around the globe. The time is now to invest in the development of dengue vaccines."

- check out the release

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.